IIP
VRTX icon

Intermede Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Intermede Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.5M Sell
101,619
-4,751
-4% -$2.11M 2.17% 22
2026
Q1 		$47.5M Sell
106,370
-27,008
-20% -$12.6M 2.2% 25
2025
Q4 		$60.5M Sell
133,378
-6,645
-5% -$2.86M 2.48% 19
2025
Q3 		$54.8M Sell
140,023
-53,892
-28% -$22.5M 2.25% 23
2025
Q2 		$86.3M Sell
193,915
-10,130
-5% -$4.67M 2.66% 22
2025
Q1 		$98.9M Buy
+204,045
New +$95.1M 3.11% 16

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Intermede Investment Partners's VRTX Position: Q2 2026 in Review

Intermede Investment Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 4.5% in Q2 2026, selling an estimated $2.11M and leaving 101,619 shares worth $51.5M. The position accounts for 2.17% of the portfolio, ranked #22.

Intermede Investment Partners first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $98.9M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Intermede Investment Partners held 101,619 shares of Vertex Pharmaceuticals worth $51.5M as of Q2 2026.
  • Intermede Investment Partners sold 4,751 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Vertex Pharmaceuticals made up 2.17% of Intermede Investment Partners's portfolio in Q2 2026, its #22 holding.
  • Intermede Investment Partners first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Intermede Investment Partners's Vertex Pharmaceuticals position peaked at $98.9M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Intermede Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.